Special Issue "Oncolytic Viruses"
Deadline for manuscript submissions: closed (31 August 2015).
Interests: Oncolytic viruses, HSV-1, clinical trials, combination treatments, virus-induced immune response, tumor microenvironment
Interests: Oncolytic viruses, adenovirus, patient-derived tumor models, combination treatments, virus-induced anti-tumor immune response, personalized viral treatment.
The concept that viruses can be employed as cancer therapeutics was already recognized in the early 1900s. Advances in our understanding of tumor and virus biology combined with developments in molecular techniques, led to a renewed interest in this field during the 1990’s. Oncolytic viruses based on engineered or naturally tumor-selective viral stains have now been the subject of a multitude of preclinical investigations and are making their way to clinical trials, with mounting evidence for safety and antitumor activity. Our understanding of their mechanism of action is rapidly growing and our view is shifting from viruses as direct tumor cell lysing agents to immune stimulating oncolytic vaccines.
This special issue of Viruses is dedicated to the use of these agents in cancer therapy. We hope to assemble a collection of research papers and reviews that together will offer a comprehensive view on this promising field, which reflects our current understanding and looks toward the future. Topics may include studies on improving oncolytic viral vectors, manipulating the virus induced immune response, role of the tumor microenvironment, mechanisms of virus-mediated cell death, viral delivery and imaging techniques, lessons from clinical trials and personalized viral therapy.
We hope this work will enrich our current understanding of oncolytic virus therapy and aid the research community in the development and clinical translation of effective virus-based anti-cancer therapies.
Prof. E. Antonio Chiocca
Dr. Martine L.M. Lamfers
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- oncolytic viruses
- oncolytic vaccines
- virus genetic engineering
- oncolytic cell killing mechanisms
- virus-microenvironment interaction
- virus-induced immune response
- virus delivery and imaging
- combination therapy